Prospective Study of Classification and Activity Assessment of Psoriatic Arthritis Based on Power Doppler (PD) Ultrasonography (PDUS)

Recruiting now

Conditions studied: Psoriatic Arthritis, Secukinumab, Ultrasonography

In brief

Psoriatic arthritis (PsA) is a complex inflammatory disease with heterogeneous clinical features, which complicates psoriasis in 30% of patients. PsA involves multiple tissues and clinical domains including skins and nails as well as arthritis, spondylitis, enthesitis, and dactylitis. Power Doppler (PD) ultrasonography (PDUS) is a sensitive non-invasive imaging technology used to assess disease activity and treatment response in PsA. This is a prospective, observational, open-label study to investigate disease activity, therapeutic response and bone destruction based on ultrasonography findings in patients with PsA.

Key facts

Study ID

NCT06730334

Run by

Nanjing Medical University

People needed

400

Starts

2023-09-01

Expected to finish

2028-06-01

Last updated by the study team

2024-12-20

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• PsA patients as defined by CASPAR criteria
• Patients must be able to comply with the visit schedule, treatment plan, laboratory tests and other study procedures
• Patients must be given informed consent

You may not qualify if…

• History of other arthritis within the last 12 months
• Concomitant disease with acute or chronic infectious diseases
• Pregnancy or laction
• Poorly tolerated with venipuncture required for blood sampling during the study

Where it is running

• Department of Rheumatology and Immunology, Jiangsu Province Hospital — Nanjing, Jiangsu, China (enrolling)
• Jiangsu Province Hospital — Nanjing, Jiangsu, China (enrolling)

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.